| Tag |
First Indicator |
Second Indicator |
Subfields |
| LEADER |
00000cam a22000007i 4500 |
| 001 |
in00005771007 |
| 005 |
20260327173723.0 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
220801s2023 ne fo 000 0 eng d |
| 040 |
|
|
|a UKAHL
|b eng
|e rda
|c UKAHL
|d UKMGB
|d OPELS
|d EMU
|d OCLCF
|d OCLCO
|d OCLCL
|d SXB
|d OCLCQ
|d OCLCL
|d SFB
|
| 015 |
|
|
|a GBC2D7607
|2 bnb
|
| 016 |
7 |
|
|a 020702543
|2 Uk
|
| 020 |
|
|
|a 9780128227114
|q (e-book)
|
| 020 |
|
|
|a 0128227117
|q (e-book)
|
| 020 |
|
|
|z 9780128227039
|q (print)
|
| 020 |
|
|
|z 9780128227114 (ePub ebook)
|
| 035 |
|
|
|a (OCoLC)1352044291
|
| 037 |
|
|
|a 9780128227114
|b Ingram Content Group
|
| 050 |
|
4 |
|a RC270
|
| 082 |
0 |
4 |
|a 616.9940758
|2 23
|
| 049 |
|
|
|a TXAM
|
| 245 |
0 |
0 |
|a Liquid biopsy :
|b new challenges in the era of immunotherapy and precision oncology /
|c edited by Antonio Russo, Ettore Capoluongo, Antonio Galvano, Antonio Giordano.
|
| 264 |
|
1 |
|a Amsterdam :
|b Academic Press,
|c [2023]
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 505 |
0 |
|
|a Front Cover -- Liquid Biopsy -- Copyright Page -- Contents -- List of contributors -- Preface -- 1 What is precision medicine in oncology? -- 1.1 Introduction: what does precision medicine mean? -- 1.2 The role of biomarkers in precision medicine -- 1.3 Classification of biomarkers -- 1.4 The rationale for the definition of tumor mutational burden -- 1.5 Collecting samples for mutational analysis: tissue or liquid biopsy? -- 1.6 Pragmatical aspects of precision medicine: how to build it? -- 1.7 Precision medicine and clinical trials: is there something different? -- 1.8 Precision medicine in oncology: what is its "area-of-application"? -- 1.9 Pharmacogenomics and precision medicine -- 1.10 Determination of programmed death-ligand 1 expression in non-small cell lung carcinoma in order to choose patients eli... -- 1.11 Through the concept of synthetic lethality: poly ADP-ribose polymerases-inhibitors and precision medicine -- 1.12 Colorectal cancer e microsatellite instability -- 1.13 Conclusions -- Conflict of interest statement -- References -- 2 Liquid biopsy: a right tool in a right context? -- Subchapter 2.1 Liquid biopsy in NSCLC -- Learning objectives -- 2.1.1 Expert opinion -- 2.1.2 Key points -- 2.1.3 Summary of clinical recommendations -- Acknowledgments -- References -- Further reading -- Subchapter 2.2 The role of mutated ctDNA in nonmalignant lesions: challenging aspects in liquid biopsy implementation -- Learning objectives -- 2.2.1 Expert opinion -- 2.2.2 Key points -- Acknowledgments -- References -- Further reading -- 3 Liquid biopsy: new challenges in the era of immunotherapy and precision oncology NGS and the other faces of molecular biology -- Learning objectives -- 3.1 Tissue or liquid biopsy? -- 3.2 Next-generation sequencing for identification of gene alterations in liquid biopsy.
|
| 505 |
0 |
|
|a 3.3 Liquid biopsy in monitoring response to therapy -- 3.4 Expert opinion -- 3.5 Key points -- 3.6 Hints for deeper insight -- References -- Further reading -- 4 Current clinically validated applications of liquid biopsy -- Learning objectives -- 4.1 Circulating tumor DNA in advanced non-small cell lung cancer -- 4.1.1 Treatment-naïve advanced non-small cell lung cancer patients -- 4.1.2 Advanced non-small cell lung cancer patients progressing during tyrosine kinase inhibitors -- 4.2 Emerging clinical applications of liquid biopsy -- 4.2.1 Colorectal cancer -- 4.2.2 Breast cancer -- 4.2.3 Melanoma -- 4.3 Liquid biopsy application in clinical research -- 4.3.1 Monitoring of treatment response in lung cancer -- 4.3.2 Monitoring of treatment response in colorectal cancer -- 4.4 Key points -- Acknowledgments -- References -- 5 Liquid biopsy and immunotherapy: is all that glitter gold? -- Learning objectives -- 5.1 Background: the need for predictive biomarkers for patient selection -- 5.1.1 Circulating tumor cells, cell-free DNA, and exosomes -- 5.1.2 Circulating tumor cells -- 5.1.3 Cell-free DNA and circulating tumor DNA -- 5.1.4 Exosomes -- 5.1.5 T-lymphocytes (the T-cell receptor) and cytokines -- 5.1.6 The soluble form of immune-checkpoints and other circulating proteins -- Abbreviations -- Key points -- Expert opinion -- Acknowledgments -- References -- 6 Which technology performs better? From sample volume to extraction and molecular profiling -- Subchapter 6.1 Molecular profiling -- Learning objectives -- 6.1.1 Expert opinion -- 6.1.2 Key points -- References -- Further reading -- Subchapter 6.2 Biological fluid withdrawal: how much sample volume is enough? -- Learning objectives -- 6.2.1 Introduction -- 6.2.2 Other body fluids used in liquid biopsy-based assays -- 6.2.3 Key points -- References -- Further reading.
|
| 505 |
0 |
|
|a Subchapter 6.3 Methods for cf/ct DNA isolation -- Learning objectives -- 6.3.1 Key points -- Acknowledgments -- References -- Further reading -- Subchapter 6.4 CTC and exosome: from the enrichment to the characterization -- Learning objectives -- 6.4.1 Introduction -- 6.4.2 Exosome enrichment -- 6.4.3 Exosomes characterization -- 6.4.3.1 Role of exosomes in immunotherapy -- 6.4.4 Circulating tumor cells enrichment methods -- 6.4.4.1 Role of circulating tumor cells in immunotherapy -- 6.4.5 Key points -- References -- Further reading -- Subchapter 6.5 Circulating RNAs (miRNA, lncRNA, etc): from the enrichment to the characterization -- Learning objectives -- 6.5.1 Introduction -- 6.5.2 Housekeeping RNAs -- 6.5.3 Regulatory ncRNAs -- 6.5.4 Key points -- 6.5.5 Expert opinion -- Acknowledgments -- References -- Further reading -- Subchapter 6.6 Cell-free/circulating tumor DNA profiling: from next-generation sequencing-based to digital polymerase chain... -- Learning objectives -- 6.6.1 Introduction -- 6.6.2 Targeted next-generation sequencing methods -- 6.6.3 Untargeted next-generation sequencing methods -- 6.6.4 Droplet digital polymerase chain reaction methods -- 6.6.5 Key points -- 6.6.6 Expert opinion -- Acknowledgments -- References -- Subchapter 6.7 Standardization and quality assurance in liquid biopsy testing -- Learning objectives -- 6.7.1 Introduction -- 6.7.2 Cell-free DNA in liquid biopsy: preanalytical limitations -- 6.7.3 The preanalytical phase of circulating tumor cells analysis -- 6.7.4 The preanalytical phase of exosomes analysis -- 6.7.4.1 Sample collection, storage, and processing -- 6.7.4.2 Exosomes isolation -- 6.7.4.2.1 Ultracentrifugation-based isolation techniques -- 6.7.4.2.2 Ultrafiltration and size exclusion chromatography -- 6.7.4.2.3 Polymer precipitation -- 6.7.4.2.4 Immunoaffinity methods.
|
| 505 |
0 |
|
|a 6.7.4.2.5 Microfluidics-based methods -- 6.7.5 Standardization initiatives and ISO/CEN/external quality assessment development in liquid biopsy -- 6.7.6 Key points -- 6.7.7 Expert opinion -- Acknowledgments -- References -- Further reading -- 7 Early detection screening: myth or reality? -- References -- 8 Molecular tumor board -- Learning objectives -- Expert opinion -- Key points -- Acknowledgments -- References -- 9 Future perspectives -- Acknowledgments -- References -- Glossary -- Index -- Back Cover.
|
| 520 |
|
|
|a Liquid Biopsy: New Challenges in the era of Immunotherapy and Precision Oncology aims to describe links between cancer, precision oncology, and liquid biopsy, focusing on their participation to immunotherapy management. The book provides updated information on the main applications of liquid biopsy and immunotherapy as well as interesting aspects useful for planning basic and translational research activities. It helps readers understand the central aspects of precision medicine in oncology, including the use of new generation technologies for translational and diagnostic settings and the main clinical trials in this area that may be useful during their research.
|
| 650 |
|
0 |
|a Biopsy.
|
| 650 |
|
0 |
|a Cancer
|x Immunotherapy.
|
| 650 |
|
0 |
|a Cancer
|x Diagnosis.
|
| 650 |
|
2 |
|a Biopsy
|
| 650 |
|
6 |
|a Biopsie.
|
| 650 |
|
6 |
|a Cancer
|x Immunothérapie.
|
| 650 |
|
6 |
|a Cancer
|x Diagnostic.
|
| 650 |
|
7 |
|a Biopsy
|2 fast
|
| 650 |
|
7 |
|a Cancer
|x Diagnosis
|2 fast
|
| 650 |
|
7 |
|a Cancer
|x Immunotherapy
|2 fast
|
| 655 |
|
7 |
|a Electronic books.
|2 local
|
| 700 |
1 |
|
|a Russo, Antonio,
|d 1956-
|e editor.
|1 https://id.oclc.org/worldcat/entity/E39PCjwr4ttfYQW36KpGY8X9Qq
|
| 700 |
1 |
|
|a Capoluongo, Ettore,
|e editor.
|
| 700 |
1 |
|
|a Galvano, Antonio,
|e editor.
|
| 700 |
1 |
|
|a Giordano, Antonio,
|c MD,
|e editor.
|1 https://id.oclc.org/worldcat/entity/E39PBJhtbKYjxPM4DCrXbY3hHC
|
| 710 |
2 |
|
|a ScienceDirect (Online service)
|
| 776 |
0 |
8 |
|i Print version :
|z 9780128227039
|
| 856 |
4 |
0 |
|u http://proxy.library.tamu.edu/login?url=https://www.sciencedirect.com/science/book/9780128227039
|z Connect to the full text of this electronic book
|t 0
|
| 955 |
|
|
|a Elsevier ScienceDirect 2026-2027
|
| 994 |
|
|
|a 92
|b TXA
|
| 999 |
f |
f |
|i b275e02b-2671-407e-b360-c37204cdc0d2
|s c7385c8e-a44c-4525-958f-eef950b96eb3
|t 0
|
| 952 |
f |
f |
|a Texas A&M University
|b College Station
|c Electronic Resources
|s www_evans
|d Available Online
|t 0
|e RC270
|h Library of Congress classification
|
| 998 |
f |
f |
|a RC270
|t 0
|l Available Online
|